119 related articles for article (PubMed ID: 31152622)
1. MYCT1 represses apoptosis of laryngeal cancerous cells through the MAX/miR-181a/NPM1 pathway.
Wang HT; Tong X; Zhang ZX; Sun YY; Yan W; Xu ZM; Fu WN
FEBS J; 2019 Oct; 286(19):3892-3908. PubMed ID: 31152622
[TBL] [Abstract][Full Text] [Related]
2. YY1 directly suppresses MYCT1 leading to laryngeal tumorigenesis and progress.
Qu SY; Sun YY; Li YH; Xu ZM; Fu WN
Cancer Med; 2017 Jun; 6(6):1389-1398. PubMed ID: 28485541
[TBL] [Abstract][Full Text] [Related]
3. MYCT1 inhibits the EMT and migration of laryngeal cancer cells via the SP1/miR-629-3p/ESRP2 pathway.
Yue PJ; Sun YY; Li YH; Xu ZM; Fu WN
Cell Signal; 2020 Oct; 74():109709. PubMed ID: 32659265
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation-induced transcriptional down-regulation of the gene MYCT1 in laryngeal squamous cell carcinoma.
Yang M; Li W; Liu YY; Fu S; Qiu GB; Sun KL; Fu WN
BMC Cancer; 2012 Jun; 12():219. PubMed ID: 22672838
[TBL] [Abstract][Full Text] [Related]
5. miR-181a targets GATA6 to inhibit the progression of human laryngeal squamous cell carcinoma.
Zhao X; Zhang W; Ji W
Future Oncol; 2018 Jul; 14(17):1741-1753. PubMed ID: 29517349
[TBL] [Abstract][Full Text] [Related]
6. MYCT1-TV, a novel MYCT1 transcript, is regulated by c-Myc and may participate in laryngeal carcinogenesis.
Fu S; Guo Y; Chen H; Xu ZM; Qiu GB; Zhong M; Sun KL; Fu WN
PLoS One; 2011; 6(10):e25648. PubMed ID: 21998677
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis.
Lei Z; Ma X; Li H; Zhang Y; Gao Y; Fan Y; Li X; Chen L; Xie Y; Chen J; Wu S; Tang L; Zhang X
Urol Oncol; 2018 Mar; 36(3):93.e23-93.e37. PubMed ID: 29066014
[TBL] [Abstract][Full Text] [Related]
8. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
9. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling.
Han P; Li JW; Zhang BM; Lv JC; Li YM; Gu XY; Yu ZW; Jia YH; Bai XF; Li L; Liu YL; Cui BB
Mol Cancer; 2017 Jan; 16(1):9. PubMed ID: 28086904
[TBL] [Abstract][Full Text] [Related]
10. miR-632 Functions as Oncogene in Hepatocellular Carcinoma via Targeting MYCT1.
Pu J; Wang J; Xu Z; Lu Y; Wu X; Wu Y; Shao Z; Tang Q; Wei H
Hum Gene Ther Clin Dev; 2019 Jun; 30(2):67-73. PubMed ID: 30982352
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of microRNA-181a may suppress proliferation and invasion and promote apoptosis of cervical cancer cells through the PTEN/Akt/FOXO1 pathway.
Xu H; Zhu J; Hu C; Song H; Li Y
J Physiol Biochem; 2016 Dec; 72(4):721-732. PubMed ID: 27534652
[TBL] [Abstract][Full Text] [Related]
12. MiR-181a Targets PHLPP2 to Augment AKT Signaling and Regulate Proliferation and Apoptosis in Human Keloid Fibroblasts.
Rang Z; Wang ZY; Pang QY; Wang YW; Yang G; Cui F
Cell Physiol Biochem; 2016; 40(3-4):796-806. PubMed ID: 27915346
[TBL] [Abstract][Full Text] [Related]
13. Interaction between microRNA-181a and TNFAIP1 regulates pancreatic cancer proliferation and migration.
Zhang P; Guo Z; Hu R; He X; Jiao X; Zhu X
Tumour Biol; 2015 Dec; 36(12):9693-701. PubMed ID: 26152285
[TBL] [Abstract][Full Text] [Related]
14. Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression.
Ting Y; Medina DJ; Strair RK; Schaar DG
Biochem Biophys Res Commun; 2010 Apr; 394(3):606-11. PubMed ID: 20214878
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
16. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
17. Renal inhibition of miR-181a ameliorates 5-fluorouracil-induced mesangial cell apoptosis and nephrotoxicity.
Liu XY; Zhang FR; Shang JY; Liu YY; Lv XF; Yuan JN; Zhang TT; Li K; Lin XC; Liu X; Lei Q; Fu XD; Zhou JG; Liang SJ
Cell Death Dis; 2018 May; 9(6):610. PubMed ID: 29795190
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of miR-181a and Fas involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis.
Zou C; Chen J; Chen K; Wang S; Cao Y; Zhang J; Sheng Y; Huang A; Tang H
Exp Cell Res; 2015 Feb; 331(2):352-61. PubMed ID: 25449696
[TBL] [Abstract][Full Text] [Related]
19. Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth.
Gu M; Wang L; Yang C; Li X; Jia C; Croteau S; Ruan X; Hardy P
Maturitas; 2018 Aug; 114():60-66. PubMed ID: 29907248
[TBL] [Abstract][Full Text] [Related]
20. MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene.
Ke G; Liang L; Yang JM; Huang X; Han D; Huang S; Zhao Y; Zha R; He X; Wu X
Oncogene; 2013 Jun; 32(25):3019-27. PubMed ID: 22847611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
